WO2026058155 - ANTIBODIES TARGETING IL-31
National phase entry is expected:
Publication Number
WO/2026/058155
Publication Date
19.03.2026
International Application No.
PCT/IB2025/059075
International Filing Date
10.09.2025
Title **
[English]
ANTIBODIES TARGETING IL-31
[French]
ANTICORPS CIBLANT IL-31
Applicants **
NOVARTIS AG
Inventors
CEBE, Regis
KOLBINGER, Frank
KOVARIK, Jiri
LIU, Hejun
MÜLLER, Kathrin
ROEDIGER, Ben
RONDEAU, Jean-Michel, René
Priority Data
63/693,617
11.09.2024
US
63/848,833
22.07.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6520 | |
| EPO | Filing, Examination, Granting | 33114 | |
| Japan | Filing, Examination, Granting | 2986 | |
| South Korea | Filing, Examination, Granting | 3790 | |
| USA | Filing, Examination, Granting | 20690 |
Total:
67,100
Contact Us
Abstract[English]
The invention relates to antibodies that bind to IL-31, including monospecific and multispecific e.g., bispecific antibodies, methods of producing the antibodies, pharmaceutical compositions comprising the antibodies, and methods of using the antibodies.[French]
L'invention concerne des anticorps qui se lient à IL-31, y compris des anticorps bispécifiques monospécifiques et multispécifiques, des procédés de production des anticorps, des compositions pharmaceutiques comprenant les anticorps, et des procédés d'utilisation des anticorps.